期刊文献+

脑膜瘤组织中中期因子蛋白的表达及意义

Expression of midkine in meningioma and its biological value
下载PDF
导出
摘要 目的探讨脑膜瘤组织中中期因子蛋白(MK)的表达及其与脑膜瘤血管生成、侵袭性、瘤周水肿和临床病理的关系。方法采用免疫组化SP法检测52例脑膜瘤组织和10例正常脑膜组织MK的表达及微血管密度(MVD),并对二者的关系进行统计学分析。结果52例脑膜瘤组织中,MK阳性表达率为63.5%,MVD为(82.0±22.7)个/HP;正常脑膜组织中无MK表达,MVD为(25.8±6.2)个/HP(P<0.05)。MK阳性表达程度与MVD呈正相关(r=0.756,P<0.05)。MK阳性表达与患者年龄、性别和肿瘤大小无关(P>0.05),而与患者病情分级、肿瘤病理分级、类型、侵袭性、瘤周水肿程度有关(P<0.05)。结论MK在脑膜瘤组织中呈过度表达,其与脑膜瘤血管生成、侵袭性、瘤周水肿及病理分级相关。 Objective To investigate the expression of midkine(MK) in meningioma and the relationship among MK with angiogenesis,invasion,peritumoral edema,and clinicopathology.Methods The expression of MK protein levels and the mean of MVD were detected by immunohisto-chemical technique(SP) in 52 meningioma tissues and 10 human normal cerebral maters.At the same time,all data were statistically analyzed.Results The positive expression rate of MK in the 52 cases was 64%,the mean of MVD in the meningiomas was(82.0±22.7)/HP.Otherwise,the expression rate of MK in the normal cerebral maters was negative, the mean of MVD in the dura was (25.8 ± 6.2)/HP the difference of MK in men- ingioma and human normal cerebral maters were significant( P 〈0.05 ). The expression of midkine was positively correlated with MVD ( r = 0. 756, P 〈 0.05 ) and MK Was not related with the patients, age, sex, and the size, location sign of tumors ( P 〉 0.05 ). The expression of MK was closely related to the patients, clinical conditions, pathological grade, invasion and peritumoral edema (P 〈 0.05). Conclusions MK overexpresses in meningiomas and is significantly correlated to tumors, angiogenesis ,invasion, pefitumoral edema and clinicopathology.
出处 《山东医药》 CAS 北大核心 2009年第30期26-28,共3页 Shandong Medical Journal
关键词 脑膜瘤 中期因子蛋白 微血管密度 meningioma midkine microvessel density
  • 相关文献

参考文献11

  • 1Kadomatsu K. The midkine family in cancer,inflammation and neural development[J]. Nagoya J Med Sci, 2005,67(3-4) :71-82.
  • 2Zou P, Muramatsu H, Sone M, et al. Mice doubly deficient in the midkine and pleiotrophingenes exhibit deficits in the expression of beta-teetorin gene and in auditory response [ J ]. Lab Invest,2006, 86(7) :645-653.
  • 3Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer [ J]. Cancer Lett ,2004,204 ( 2 ) : 127-143.
  • 4Toyoda E, Doi R, Kami K. Midkine promoter-based conditionally replieafive adenovirus therapy for midkine-expressing human pancreatic eoncer- J Exp Clin Cancer Res,2008,4(20) :27-30.
  • 5Jin Z, Lahat G, Korchin B, et al. Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target[ J]. Clin Cancer Res,2008,14 (16) :5033-5042.
  • 6Tanabe K, Matsumoto M, Ikematsu S. Midkine and its clinical significance in endometrial carcinoma[ J]. Cancer Sci ,2008,99(6 ) : 1125-1130.
  • 7Kohno S, Nakagawa K, Hanmda K,et al. Midkine promoter based conditlon-ally replicative adenovirus for malignant glloma therapy [ J]. Oncol Rep,2004,12( 1 ) : 73-78.
  • 8Yu L,Yanmmoto N,Kadomatsu K,et al. Midkine promoter can mediate transcriptional activation of a fused suicide gene in a broader range of human breast cancer compared with c-erbB-2 promoter [J].Oncology,2004,66 (2) :143-149.
  • 9Tong Y, Mentlein R, Buhl R, et al. Overexpression of midkine contributes to anti-apoptotic effects in human meninglomas[J]. J Neurochem ,2007, 100 (4) : 1097-1107.
  • 10LaMszus K, Lengler U, Schmidt NO, et al. Vascular endothelial growth factor hepatocyte growth factor/scatter factor, basic fibroblast growt hfactor, an d placenta growth factor in huan m meningioma s an d their relationtoangiogenesis and malignancy [J]. Neurosurgery, 2000,46 ( 4 ) : 938 -948.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部